Reply to Letter
Reply
Anthony H. Schapira MD, DSc, FRCP, FMedSci,
Anthony H. Schapira MD, DSc, FRCP, FMedSci
Institute of Neurology and National Hospital for Neurology and Neurosurgery, University College London, London, UK
Search for more papers by this author C. Warren Olanow MD, FRCPC,
C. Warren Olanow MD, FRCPC
Mount Sinai Medical School, New York, NY
Search for more papers by this author
Anthony H. Schapira MD, DSc, FRCP, FMedSci,
Anthony H. Schapira MD, DSc, FRCP, FMedSci
Institute of Neurology and National Hospital for Neurology and Neurosurgery, University College London, London, UK
Search for more papers by this author C. Warren Olanow MD, FRCPC,
C. Warren Olanow MD, FRCPC
Mount Sinai Medical School, New York, NY
Search for more papers by this author
First published: 27 April 2009
No abstract is available for this article.
References
- 1
Goetz CG,
Poewe W,
Rascol O,
Sampaio C.
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Mov Disord
2005;
20:
523–539.
- 2
Pahwa R,
Factor SA,
Lyons KE, et al.
Quality Standards Subcommittee of the American Academy of Neurology.
Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology
2006;
66:
983–995.
- 3
National Institute of Clinical Excellence (NICE). Parkinson's disease guidelines
2006. Available at: www.nice.org.uk
